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Background
The failure of a recombinant adenovirus serotype 5 (rAd5)
vector-based vaccine for HIV-1 in a phase 2b efficacy study
in humans calls for efforts to develop novel vaccination
strategies.
Methods
In this study, we developed a recombinant replication-
competent modified vaccinia Tiantan (MVTT), namely
rMVTTSIVgpe, as a mucosal vaccine expressing SIVmac Gag,
Pol and Env. The immunogenicity and efficacy of
rMVTTSIVgpe was studied in combination with an rAd5-
based vaccine rAd5SIVgpe in Chinese macaques (Macaca
mulatta) without the protective MHC class I allele Mamu-
A*01. rMVTTSIVgpe was given through intranasal and oral
inoculations whereas rAd5SIVgpe was given through intra-
muscular injection. Four macaques in each of the four
study groups received the following prime and boost vac-
cinations: rMVTTSIVgpe/rAd5SIVgpe; rMVTTSIVgpe/rAd5SIVgpe,
twice; rAd5SIVgpe/rAd5SIVgpe; and placebo controls, respec-
tively.
Results
We found that the heterologous rMVTTSIVgpe/rAd5SIVgpe
regimen elicited cellular immune responses with
enhanced magnitude, breadth, sustainability, and poly-
functionality when compared with the homologous
rAd5SIVgpe regimen. Higher levels of neutralizing antibody
(Nab) responses were also induced by the rMVTTSIVgpe/
rAd5SIVgpe regimen. These Nab responses, however, neu-
tralized SIVmac1A11 but not SIVmac239. The additional
round of rMVTTSIVgpe/rAd5SIVgpe vaccinations did not
enhance the immune responses further. After intrarectal
challenge with a pathogenic and Chinese macaque-
adapted SIVmac239 (5 × 105 TCID50 per animal), one of
four monkeys vaccinated with the rMVTTSIVgpe/rAd5SIVgpe
regimen was fully protected whereas the rest showed an
average of 1.96 log and 2.22 log reduction of peak and set-
point (6 weeks post challenge) viral loads as compared
with control animals.
Conclusion
These data demonstrate that the rMVTTSIVgpe/rAd5SIVgpe
regimen induced durable partial immune control of a
pathogenic, neutralization-resistant SIVmac239 chal-
lenge. Our findings have critical implications for further
optimization of vaccination strategies against HIV-1 by
engaging the mucosal immune system.
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